Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Fritz H Schröder, Jonas Hugosson, Monique J Roobol, Teuvo L J Tammela, Marco Zappa, Vera Nelen, Maciej Kwiatkowski, Marcos Lujan, Liisa Määttänen, Hans Lilja, Louis J Denis, Franz Recker, Alvaro Paez, Chris H Bangma, Sigrid Carlsson, Donella Puliti, Arnauld Villers, Xavier Rebillard, Matti Hakama, Ulf-Hakan StenmanPaula Kujala, Kimmo Taari, Gunnar Aus, Andreas Huber, Theo H van der Kwast, Ron H N van Schaik, Harry J de Koning, Sue M Moss, Anssi Auvinen

Research output: Contribution to journalArticlepeer-review

Abstract

The European Randomised study of Screening for Prostate Cancer (ERSPC) has shown significant reductions in prostate cancer mortality after 9 years and 11 years of follow-up, but screening is controversial because of adverse events such as overdiagnosis. We provide updated results of mortality from prostate cancer with follow-up to 2010, with analyses truncated at 9, 11, and 13 years.
Original languageEnglish
Pages (from-to)2027-2035
JournalThe Lancet
Volume384
Issue number9959
DOIs
Publication statusPublished - 2014

Subject classification (UKÄ)

  • Medicinal Chemistry

Fingerprint

Dive into the research topics of 'Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.'. Together they form a unique fingerprint.

Cite this